Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neuphoria Therapeutics (NEUP) Consolidated Net Income (2024 - 2025)

Neuphoria Therapeutics has reported Consolidated Net Income over the past 2 years, most recently at $1.9 million for Q4 2025.

  • Quarterly Consolidated Net Income rose 195.92% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.1 million through Dec 2025, down 123.15% year-over-year, with the annual reading at -$838059.0 for FY2025, 93.87% up from the prior year.
  • Consolidated Net Income was $1.9 million for Q4 2025 at Neuphoria Therapeutics, up from -$9.9 million in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $11.3 million in Q1 2025 and troughed at -$9.9 million in Q3 2025.